T Cell News and Research

Latest T Cell News and Research

CTC counting can determine lung cancer aggressiveness, predict best treatment

CANCER RESEARCH UK scientists have found that counting the number of lung cancer cells circulating in the blood could determine how aggressive the cancer is and predict the best treatment to use.

22 Mar 2011

VirWall launches new UV sanitizer to eliminate bacteria, virus from communication devices

ViraShield, the new UV sanitizer introduced by VirWall Systems Inc., is the first multi-purpose device of its kind that takes only seconds to rid those products we've come to depend on of the bacteria and viruses that typically crawl, breed and cover the surfaces of our personal communications devices.

22 Mar 2011

Scientists develop new method for gene regulation study

Scientists at the European Molecular Biology Laboratory in Heidelberg, Germany, have developed a new method for studying gene regulation, by employing a jumping gene as an informant. Published online today in Nature Genetics, the new method is called GROMIT.

22 Mar 2011

Study: Stem cell transplant may benefit patients with rapidly progressive MS

A long term study reports about the effectiveness of replacing bone marrow, purposely destroyed by chemotherapy, with autologous stem cell rescue for people with aggressive forms of multiple sclerosis.

22 Mar 2011

CMU's CNAST receives DSF Charitable Foundation grant to develop novel biomedical tools

The DSF Charitable Foundation has given a $3.9 million grant to Carnegie Mellon University's Center for Nucleic Acids Science and Technology to further the development of novel biomedical tools targeted at monitoring and manipulating gene expression.

22 Mar 2011

City Of Hope opens new center for diabetes research and care

City of Hope has established a new Diabetes Research Center that will expand its pioneering investigations into diabetes, endocrinology and metabolic diseases, create an infrastructure to support translational research and enhance clinical care for diabetes and its related complications.

22 Mar 2011

USPTO grants patent to HistoRx methods for digital microscopy standardization

HistoRx, Inc., announced today that the U.S. Patent and Trademark Office has granted a patent protecting the company's methods for standardization of digital microscopy instruments in order to go beyond imaging to generating high-quality reproducible data that precisely relates to biomarker concentrations in tissue sections.

22 Mar 2011

Cephalon to acquire Gemin X Pharmaceuticals

Cephalon, Inc. announced today that it has signed a definitive merger agreement under which it will acquire all of the outstanding capital stock of Gemin X Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing first-in-class cancer therapeutics, for $225 million cash on a cash-free, debt-free basis. Gemin X stockholders could also receive up to $300 million in cash payments upon the achievement of certain regulatory and sales milestones.

22 Mar 2011

Second US trial in HIV/AIDS lymphoma patients using Benitec’s ddRNAi technology

Benitec Limited (ASX:BLT), a company involved in RNA-based gene silencing for human therapeutics, announced that the City of Hope research hospital in Duarte, California is planning to initiate a second small Phase I/II study using Benitec’s DNA-directed RNA interference (ddRNAi) technology in lymphoma patients carrying the HIV virus. The aim of the study is to optimize the treatment by modifying a range of clinical parameters.

21 Mar 2011

Differences between therapeutic radiation therapy and exposure to excessive nuclear plant fallout radiation

"The Canadian Association of Radiation Oncology (http://www.caro-acro.ca) is the voice for specialists in Canada who treat patients' cancer with radiation. In that capacity," explains Dr. Matthew Parliament, president of CARO-ACRO, "we work with proven, controlled, targeted application of various forms of radiation therapy to treat and cure cancer."

21 Mar 2011

China PharmaHub, University of California enter license agreement for stem cell universal donor blood product

China PharmaHub Corp., a biopharmaceutical acquisition and development company, today announced that it has signed a exclusive worldwide license agreement with the University of California, for worldwide rights to develop, commercialize and market a universal donor blood product derived from embryonic stem cells developed by UCSD Associate Professor of Medicine and Pediatrics Dr. Ewa Carrier.

21 Mar 2011

Study unravels molecular mechanism of biomolecule RNA that plays dynamic regulatory role in protein selection

If a big bunch of your brain cells suddenly went rogue and decided to become fat cells, it could cloud your decision-making capacity a bit. Fortunately, early in an organism's development, cells make firm and more-or-less permanent decisions about whether they will live their lives as, say, skin cells, brain cells or, well, fat cells.

21 Mar 2011

Sarsia Seed provides follow-up funding for APIM Therapeutics

APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.

21 Mar 2011

Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from a Phase II clinical trial of intravenous Phenoxodiol in combination with cisplatin in women with platinum-resistant ovarian cancer.

21 Mar 2011

WaferGen, NuGEN collaborate to develop integrated workflows for gene expression profiling and target enrichment

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, and NuGEN Technologies, Inc., a leader in innovative genomic samples preparation, today announced they will co-develop and co-market simple, seamlessly integrated workflows for gene expression profiling and target enrichment to enable researchers to more easily achieve high-throughput, high-density real-time PCR with small, degraded, and hard-to-replace clinical specimens, such as formalin fixed paraffin embedded tissue (FFPE).

21 Mar 2011

Finesse launches new core modules for off-line data processing in fourth generation TruBio DV software

Finesse Solutions, LLC, a manufacturer of measurement and control solutions for life science process applications, has announced the official launch of two new core modules for off-line data processing in its fourth generation TruBio DV software. These modules are targeted at enabling bioprocessing specialists to manage data from third party equipment and process analyzers, and obtain automated electronic records of their batch.

21 Mar 2011

Research outlines how cilia disease gene products regulate early cilium formation

An international collaboration jointly led by University College Dublin, University of Alabama and Simon Fraser University, British Columbia has outlined in the Journal of Cell Biology how cilia disease gene products regulate important aspects of early cilium formation and the integrity of the ciliary transport gate.

21 Mar 2011

Advanced Cell Technology reduces 2010 debt to less than $1 million

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today 2010 year-end results for the period ended December 31, 2010. The Company utilized $8.8 million in cash for operations during the year, compared to $5.1 million in the year-earlier period.

21 Mar 2011

More opportunities to develop therapies for protein misfolding

Romping clumps of misfolded proteins are prime suspects in many neurological disorders including Alzheimer's, Parkinson's, and Creutzfeld-Jakob Disease. Those diseases are devastating and incurable, but a team of biologists at Brown University reports that cells can fix the problems themselves with only a little bit of help. The insight suggests that there are more opportunities to develop a therapy for protein misfolding than scientists had thought.

21 Mar 2011

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced a positive outcome from a pivotal Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class hedgehog pathway inhibitor, in patients with advanced basal cell carcinoma (BCC).

21 Mar 2011

T Cell News and Research

Latest T Cell News and Research

CTC counting can determine lung cancer aggressiveness, predict best treatment

VirWall launches new UV sanitizer to eliminate bacteria, virus from communication devices

Scientists develop new method for gene regulation study

Study: Stem cell transplant may benefit patients with rapidly progressive MS

CMU's CNAST receives DSF Charitable Foundation grant to develop novel biomedical tools

City Of Hope opens new center for diabetes research and care

USPTO grants patent to HistoRx methods for digital microscopy standardization

Cephalon to acquire Gemin X Pharmaceuticals

Second US trial in HIV/AIDS lymphoma patients using Benitec’s ddRNAi technology

Differences between therapeutic radiation therapy and exposure to excessive nuclear plant fallout radiation

China PharmaHub, University of California enter license agreement for stem cell universal donor blood product

Study unravels molecular mechanism of biomolecule RNA that plays dynamic regulatory role in protein selection

Sarsia Seed provides follow-up funding for APIM Therapeutics

Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer

WaferGen, NuGEN collaborate to develop integrated workflows for gene expression profiling and target enrichment

Finesse launches new core modules for off-line data processing in fourth generation TruBio DV software

Research outlines how cilia disease gene products regulate early cilium formation

Advanced Cell Technology reduces 2010 debt to less than $1 million

More opportunities to develop therapies for protein misfolding

Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma

Immunology eBook

A new method to measure intracellular water in biological systems

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

A new method to measure intracellular water in biological systems

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

Newsletters you may be interested in